Inogen, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2024

The activity for stock options under the Company’s stock plans for the three months ended March 31, 2024 is as follows:


								Remaining
								weighted-
						Weighted-		average		Per share
						average		contractual		average
				Price per		exercise		terms		intrinsic
	Options			share		price		(in years)		value
Outstanding as of December 31, 2023		20,000		$	83.30	$	83.30		0.36	$	—
Forfeited		(10,000	)		83.30		83.30
Outstanding as of March 31, 2024		10,000			83.30		83.30		0.11		—
Vested and exercisable as of March 31, 2024		10,000			83.30		83.30		0.11		—
Vested and expected to vest as of March 31, 2024		10,000		$	83.30	$	83.30		0.11	$	—

Summary of Restricted Stock Activity

Stock Awards activity for the three months ended March 31, 2024 is summarized below:


										Weighted-
										average
										grant
				Performance						date fair
				and						value
Restricted stock units	Time-based			time-based			Total			per share
Unvested restricted stock units as of December 31, 2023		1,146,404			346,688			1,493,092		$	14.67
Granted		608,174			235,000			843,174			6.95
Vested		(163,446	)		—			(163,446	)		20.81
Forfeited/canceled		(28,856	)		(103,850	)		(132,706	)		19.58
Unvested restricted stock units as of March 31, 2024 (1)		1,562,276			477,838			2,040,114		$	10.96
Unvested and expected to vest restricted stock units outstanding as of March 31, 2024								1,625,427		$	11.03

(1) Outstanding restricted stock units are based on the maximum payout of the targeted number of shares.

Summary of Stock-based Compensation Expense

Stock-based compensation expense recognized for the three months ended March 31, 2024 and 2023, was as follows:


	Three months ended
	March 31,
	2024		2023
Stock-based compensation expense by type of award:
Restricted stock units and restricted stock awards	$	2,309	$	3,305
Employee stock purchase plan		107		137
Total stock-based compensation expense	$	2,416	$	3,442

For the three months ended March 31, 2024 and 2023, respectively, stock-based compensation expense recognized under ASC 718, included in cost of revenue, research and development expense, sales and marketing expense, and general and administrative expense was as follows:


	Three months ended
	March 31,
	2024		2023
Cost of revenue	$	180	$	84
Research and development		460		458
Sales and marketing		430		774
General and administrative		1,346		2,126
Total stock-based compensation expense	$	2,416	$	3,442